Announcements Trials

Browse Landscape

Phase

Status

Unknown 3 Completed 2 Withdrawn 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1780 Neoplasms 1500 Carcinoma, Non-Small-Cell Lung 1045 Prostatic Neoplasms 958 Colorectal Neoplasms 882 Lung Neoplasms 803 Pancreatic Neoplasms 573 Carcinoma, Hepatocellular 543 Leukemia, Myeloid, Acute 541 Stomach Neoplasms 513 Ovarian Neoplasms 508 Neoplasm Metastasis 499 Multiple Myeloma 494 Recurrence 412 Melanoma 387 Squamous Cell Carcinoma of Head and Neck 370 Brain Neoplasms 362 Uterine Cervical Neoplasms 361 Head and Neck Neoplasms 356 Esophageal Neoplasms 312 Precursor Cell Lymphoblastic Leukemia-Lymphoma 310 Lymphoma 306 Endometrial Neoplasms 305 Triple Negative Breast Neoplasms 299 Glioblastoma 299 Rectal Neoplasms 282 Sarcoma 266 Urinary Bladder Neoplasms 264 Hematologic Neoplasms 264 Colonic Neoplasms 255

Interventions

pembrolizumab 1 Paclitaxel 1 Carboplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Squamous Non-small Cell Lung Cancer × Clear all

NCT07221474 2026-05-28

INTerpath-13

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡